eFinder

eFinder

Home › GLP-1 Drug Efficacy and Risk › Article

'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk, report finds

Cnbc · · 618 words · By Elsa Ohlen
GLP-1 Drug Efficacy and Risk Pharmaceutical Market Volatility Corporate R&D Concentration
open_in_new Read the original article: https://www.cnbc.com/2026/05/04/wegovy-glp1-weight-loss-drugs-pharma-growth-bubb…

psychologyDetected Techniques

warning
Loaded Language 80% confidence
Using words with strong emotional connotations to influence an audience.
warning
Exaggeration / Hyperbole 70% confidence
Overstating facts or claims to create a stronger emotional response.

fact_checkFact-Check Results

11 claims extracted and verified against multiple sources including cross-references, web search, and Wikipedia.

info Single Source 5
help Insufficient Evidence 2
cancel Disputed 1
check_circle Corroborated 1
verified Verified 1
schedule Pending 1
cancel
“Pharmaceutical R&D returns for the world's top 20 pharma companies have improved for a third consecutive year to 7%”
DISPUTED
The claim states returns improved to 7%. However, the Deloitte UK evidence explicitly states that combined R&D returns rose to 5.9% in 2024, not 7%.
menu_book
wikipedia NEUTRAL — D.R. Horton, Inc. is an American home construction company based in Arlington, Texas. Since 2002, the company has been the largest homebuilder by volume in the United States. The company ranked number…
https://en.wikipedia.org/wiki/D._R._Horton
menu_book
wikipedia NEUTRAL — Dattatreya Ramchandra Kaprekar (Marathi: दत्तात्रेय रामचंद्र कापरेकर; 17 January 1905 – 4 July 1986) was an Indian recreational mathematician who described several classes of natural numbers includin…
https://en.wikipedia.org/wiki/D._R._Kaprekar
menu_book
wikipedia NEUTRAL — Research and development (R&D or R+D) is the set of innovative activities undertaken by corporations, wealthy industrialists (such as Alfred Lee Loomis), or governments in developing new services or p…
https://en.wikipedia.org/wiki/Research_and_development
+ 3 more evidence sources
info
“for the first time in 16 years, oncology has been surpassed as the largest contributor to late-stage pipeline value by obesity treatments”
SINGLE SOURCE
The provided evidence for this claim consists of general Wikipedia and WHO entries on obesity, which do not mention pipeline value or oncology comparisons. No specific source corroborates the '16 years' or 'surpassed oncology' claim.
menu_book
wikipedia NEUTRAL — Abdominal obesity, also known as central obesity and truncal obesity, is the human condition of an excessive concentration of visceral fat around the stomach and abdomen to such an extent that it is l…
https://en.wikipedia.org/wiki/Abdominal_obesity
menu_book
wikipedia NEUTRAL — Obesity is a medical condition, considered a disease by multiple organizations, in which excess body fat has accumulated to such an extent that it can have negative effects on health. People are clas…
https://en.wikipedia.org/wiki/Obesity
menu_book
wikipedia NEUTRAL — Obesity is common in the United States and is a major health issue associated with numerous diseases, specifically an increased risk of certain types of cancer, coronary artery disease, type 2 diabete…
https://en.wikipedia.org/wiki/Obesity_in_the_United_States
+ 3 more evidence sources
info
“Drugs that target obesity and diabetes now account for an estimated 38% of all projected commercial inflows from the 2025 late-stage pipeline”
SINGLE SOURCE
The provided evidence consists of general medical definitions of obesity and does not contain the specific 38% figure for 2025 late-stage pipeline inflows.
menu_book
wikipedia NEUTRAL — Abdominal obesity, also known as central obesity and truncal obesity, is the human condition of an excessive concentration of visceral fat around the stomach and abdomen to such an extent that it is l…
https://en.wikipedia.org/wiki/Abdominal_obesity
menu_book
wikipedia NEUTRAL — Obesity classification is a ranking of obesity, the medical condition in which excess body fat has accumulated to the extent that it has an adverse effect on health. The World Health Organization (WHO…
https://en.wikipedia.org/wiki/Classification_of_obesity
menu_book
wikipedia NEUTRAL — Obesity is a medical condition, considered a disease by multiple organizations, in which excess body fat has accumulated to such an extent that it can have negative effects on health. People are clas…
https://en.wikipedia.org/wiki/Obesity
+ 3 more evidence sources
info
“If GLP-1/GIP assets are excluded from the analysis, the industry's rate of return drops to just 2.9%, a decline from 3.8% in 2024”
SINGLE SOURCE
The evidence provided includes general lists of pharma companies and drug descriptions (Tirzepatide), but does not mention the specific rate of return drop to 2.9% when excluding GLP-1/GIP assets.
menu_book
wikipedia NEUTRAL — ATC code A10 Drugs used in diabetes is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (W…
https://en.wikipedia.org/wiki/ATC_code_A10
menu_book
wikipedia NEUTRAL — Eucalyptus Health is an Australian digital health company founded in 2019 that operates telehealth services including Pilot (men's health), Juniper (women's weight management and menopause), Software …
https://en.wikipedia.org/wiki/Eucalyptus_Health
menu_book
wikipedia NEUTRAL — Tirzepatide is a gastric inhibitory polypeptide (GIP) analog and a GLP-1 receptor agonist. It is used as an antidiabetic medication to treat type 2 diabetes and for weight loss. Tirzepatide is adminis…
https://en.wikipedia.org/wiki/Tirzepatide
+ 3 more evidence sources
check_circle
“Obesity assets now represent about 25% of total forecast sales of the late-stage pipeline, while oncology's share has slipped to 20%”
CORROBORATED
Multiple web search results from Deloitte and other sources confirm that obesity assets represent about 25% of total forecast sales of the late-stage pipeline and oncology's share has slipped to 20%.
travel_explore
web search NEUTRAL — Obesity assets represent about 25% of total forecast sales of the late-stage pipeline, while oncology's share has slipped to 20%, Deloitte found.
https://torre.news/bubble-effect-weight-loss-drug-fueled-gro…
travel_explore
web search NEUTRAL — The share sale could give the company a valuation.. India, the world's third-largest emitter of.. Article deleted. 'Bubble effect': Weight loss drug fueled growth is putting the pharma sector at risk,…
https://vk.com/wall-144627768_96930
travel_explore
web search NEUTRAL — Oncology assets contribute 20 percent of the late-stage forecast value in 2025 (down from 26 percent in 2024).
https://www.deloitte.com/global/en/industries/life-sciences-…
info
“the obesity sector... contributed just 1% of the projected value as recently as 2022”
SINGLE SOURCE
The evidence provided discusses acquisitions in 2022 and general obesity trends, but does not confirm the specific figure that the sector contributed 'just 1% of the projected value' in 2022.
travel_explore
web search NEUTRAL — Obesity sector is also known as Obesity Management or Obesity Treatment.Last year, in 2022, a total of 2 acquisitions happened in Obesity sector in United States.
https://tracxn.com/d/explore/obesity-startups-in-united-stat…
travel_explore
web search NEUTRAL — The regulatory approval in April 2026 of the first small daily oral GLP-1 pill, which can be taken without restrictions on food or timing, opens the door to an entirely new phase in obesity treatment …
https://samer-choucair.com/samer-choucair-foundayo-is-not-ju…
travel_explore
web search NEUTRAL — China, India, and the US will face significant health and economic challenges by 2050, with over 3.8 billion adults projected to be overweight or obese. The rising obesity rates could severely impact …
https://economictimes.indiatimes.com/topic/obesity-sector
verified
“Deloitte found that just 54 mega-blockbuster indications, representing only 9% of the late-stage cohort, are projected to generate roughly 70% of total risk-adjusted peak sales”
VERIFIED
A Deloitte Switzerland report explicitly confirms that 54 blockbuster asset-indications (approx 9% of the cohort) are projected to generate around 70% of total risk-adjusted peak sales in 2025.
travel_explore
web search NEUTRAL — In 2025, just 54 blockbuster asset-indications, representing approximately 9 per cent of the late-stage cohort, are projected to generate around 70 per cent of total risk-adjusted peak sales (see Figu…
https://www.deloitte.com/ch/en/Industries/life-sciences-heal…
travel_explore
web search NEUTRAL — Risk of Covid-19 among front-line health-care workers and the general...
https://www.thelancet.com/journals/lanpub/article/PIIS2468-2…
travel_explore
web search NEUTRAL — An alopecia areata indication has near-blockbuster potential. Now that I have established Olumiant could be a game-changing treatment for the estimated 147 million around the world who live with alope…
https://www.fool.com/investing/2021/10/21/is-this-eli-lillys…
info
“Novo Nordisk's GLP-1 is approved for reducing cardiovascular risks and treating patients with liver and kidney disease”
SINGLE SOURCE
The evidence confirms Novo Nordisk's GLP-1 (Wegovy) is approved for weight management, but the provided snippets do not explicitly confirm approval for liver and kidney disease, only cardiovascular risks are typically associated with these drugs in recent news (though not explicitly detailed in the provided snippets).
travel_explore
web search NEUTRAL — Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 28.1% of its shares and a majority of its voting shares.
https://en.wikipedia.org/wiki/Novo_Nordisk
travel_explore
web search NEUTRAL — Novo Nordisk milestone in obesity care Novo Nordisk has announced FDA approval of the Wegovy pill (oral semaglutide 25 mg) the first oral GLP-1 receptor agonist approved for chronic weight management …
https://www.linkedin.com/posts/digvijay-bachhav-88173082_nov…
travel_explore
web search NEUTRAL — Pathogen-host- environment interplay and disease emergence.
https://www.tandfonline.com/toc/temi20/current
help
“Eli Lilly's GLP-1/GIP combo is approved for treating sleep apnea in people with obesity”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results to support or refute this claim.
help
“Novo published the result of a years-long clinical trial studying the effect of semaglutide... on slowing the progression of Alzheimer's disease. The trial failed to show a significant delay of disease progression”
INSUFFICIENT EVIDENCE
No evidence was found in the provided search results to support or refute this claim.
schedule
“GLP-1s have also been shown to help patients struggling with addiction”
PENDING
info Disclaimer: This analysis is generated by AI and should be used as a starting point for critical thinking, not as definitive truth. Claims are verified against publicly available sources. Always consult the original article and additional sources for complete context.